Big Pharma flinches in opioids suits: a J&J loss in Okla. and a Sackler bid

Patrick Malone & Associates P.C. | DC Injury Lawyers
Contact

Patrick Malone & Associates P.C. | DC Injury Lawyers

Big Pharma has hit at least two pain points of potential significance as government officials and trial lawyers work to hold drug makers accountable for at least some of the carnage caused by prescription painkillers.

There’s still a far way to go before companies see a full legal reckoning in the civil justice system for opioid overdose deaths that have killed an estimated 400,000 Americans since 2007, as well the drugs causing tens of thousands of cases of suffering and addiction.

But Oklahoma officials have struck hard at pharmaceutical interests by winning a $572-million nuisance ruling from a state judge against Johnson and Johnson, a legendary and once-respected health care brand.

This legal landmark was followed by news that several drug makers — most notably the plutocratic Sackler family and their oxycodone-making firm Purdue pharmaceutical — may be ready to settle thousands of legal claims by paying billions of dollars and even giving up a business that has enriched them in almost unimaginable fashion.

Lots of ink and electrons have been spilled in excellent news articles and analyses. There are some key points to watch and take not of, though, in the two sizable developments in the nation’s opioid crisis.

Johnson and Johnson’s big bad day in court

J&J long has held itself out as a special, family-focused company in health care. Its much-promoted reputation collided with reality in the Oklahoma court, where the company not only became the big target of a state lawsuit but also the last defendant standing when two other firms, including Purdue and Teva, settled.

J&J has built a reputation in court of battling claims against it, though the company has run its court room record aground with significant losses in cases disputing “whether its talcum powder led to ovarian cancer, and high-profile [matters] over other potentially flawed products, like pelvic mesh and the anti-stroke drug Xarelto, which has caused excessive bleeding,” the New York Times reported.

In Oklahoma, J&J asserted that its opioid sales were low and that it had little legal culpability for deaths and injuries caused by prescription painkillers. The company pointed to other Big Pharma firms and said its activities with the powerful drugs were allowed and approved under the law.

But state officials pursued a different legal theory, arguing that the health care giant had created a public nuisance for which Oklahoma was owed $17 billion, so it could remedy the harms over the next two decades.

Why this approach? As Bloomberg news service reported:

“The governments turned to the nuisance theory because it doesn’t require them to prove individual doctors were lured into overprescribing the opioid painkillers. Instead, they can use experts to show the companies’ marketing as a whole was deceptive and led to a jump in addictions and often-fatal overdoses.”

The New York Times reported that “Judge Thad Balkman of Cleveland County District Court, heartened lawyers representing states and cities — plaintiffs in many of the more than 2,000 opioid lawsuits pending across the country — who are pursuing [this nuisance] legal strategy.” The newspaper added:

“In his ruling, [the judge] wrote that Johnson & Johnson had promulgated ‘false, misleading, and dangerous marketing campaigns’ that had ‘caused exponentially increasing rates of addiction, overdose deaths’ and babies born exposed to opioids … Johnson & Johnson, which contracted with poppy growers in Tasmania, supplied 60% of the opiate ingredients that drug companies used for opioids like oxycodone, the state argued, and aggressively marketed opioids to doctors and patients as safe and effective. A Johnson & Johnson subsidiary, Janssen Pharmaceuticals, made its own opioids — a pill whose rights it sold in 2015, and a fentanyl patch that it still produces. Judge Balkman said the $572 million judgment could pay for a year’s worth of services needed to combat the epidemic in Oklahoma.”

So, with that smaller payment ordered, what message did Judge Balkman send? As the news and information site Axios reported:

“The judgment is less than 4% of J&J’s net profit from 2018, and significantly less than the $2 billion some Wall Street analysts expected J&J to end up paying — and that’s why shares of J&J and other related companies soared in after-hours trading. If this case is used as a benchmark in the national lawsuit, J&J likely would pay billions — but again, not an insurmountable amount for a company that brings in more than $80 billion of sales annually … J&J plans to appeal, saying in a statement the judge’s decision was ‘flawed’ and that it is ready to extend this fight into 2021.”

The Sacklers start to crumble?

In Cleveland, a federal judge has struggled for a while now to deal with thousands of lawsuits, consolidated in his court, and claiming that states, counties, cities, Indian tribes, and others have suffered costly harm due to the opioid abuse and overdose crisis. The federal judge lacks effective sway over actions like the case pursued in the state courts in Oklahoma.

But the timing of the western state decision may have worked for the many disputing parties, giving them a chance to see how various legal approaches might play out in court.

For companies lacking the deep resources of J&J, the Oklahoma suit may have spelled grim consequences ahead. Teva and Purdue settled rather than go to trial.

Then, after the J&J ruling was handed down, word began to leak out that Purdue and the Sackler family were negotiating a “global” settlement, an accord that would see them effectively give up their golden goose enterprise and as much as $12 billion to resolve thousands of suits against the firm. The New York Times described the complex corporate machinations that would occur, noting that the scoop about the talks was broken by NBC news:

“The bulk of the [settlement] funds would come from restructuring the company under a Chapter 11 bankruptcy filing that would transform it from a private company into a ‘public beneficiary trust.’ That would allow the profits from all drug sales, including the opioid painkiller OxyContin, to go to the plaintiffs — largely states, cities, towns and tribes. In addition, the company would give its addiction treatment drugs to the public without cost. Those drugs are currently under development and have received fast-track review status by the Food and Drug Administration. They include tablets to blunt opioid cravings and an over-the-counter nasal spray to reverse overdoses. The value of the profits from the new trust and the drug donations is estimated to total between $7 billion and $8 billion. In addition to their $3 billion cash payout, the Sacklers would sell another drug company they own, Mundipharma, and contribute an additional $1.5 billion from the proceeds.”

NPR reported that the Sacklers might be joined by Endo International, Allergan, and, yes, J&J in a negotiated settlement.

The talks are confidential, continuing, and uncertain as to their outcome. Axios, quoting NBC, again puts in perspective the possibility of a settlement for the Sacklers, who have seen their family history of philanthropy sacked by the opioid scandals, including embarassing revelations pouring forth from ProPublica and ABC news, based on files unsealed in a lawsuit by the medical and health news site Stat:

“The family is worth an estimated $13 billion, and Purdue made more than $35 billion from OxyContin sales…”

If the Sacklers, for example, walk away with their family name preserved, along with a chunk of their fortune, will that not only take care of medical and other needs of those harmed by opioids but also give angry plaintiffs a sense that they got justice for wrongs committed against them? Further complicating discussions about a fair and equitable settlement is the complexity of the Sackler fortunes, which already may be dispersed in hard to find and account for global holdings, the Associated Press reported.

Risky forecasting

In my practice, I see not only the harms that patients suffer while seeking medical services, but also the ordeals they may go through to start to try to be made whole through actions in the civil justice system, notably medical malpractice suits. Lawsuit can take time and resources, and the legal processes entailed with them can be daunting if not downright scary to those unfamiliar with the courts and the law.

A sense that wrongs will be not only recognized publicly but also remedied in some fashion can help sustain patients in long-running suits, especially complex matters involving large enterprises (whether they are big hospitals or Big Pharma firms). But plaintiff lawyers need to temper righteous optimism with realities, especially in difficult cases like those involving Big Pharma and opioids. Favorable court rulings can’t bring back the dead or easily fix those injured by addiction, pain, and the decline tied to opioid abuse.

And with large, complex cases, there inevitably will be — and already has been — disputes among the claimants. States already have argued in negotiations that they should hold first sway over any prospective settlements with awards, with their claims ahead of counties, who, in turn, say they have greater claims than do cities. Exactly how settlements get awarded and split up also can become divisive quickly, as Ohio is showing with the state officials battling over action in the legislature to empower the attorney general and the state to take over opioid-related lawsuits filed against Big Pharma by cities and counties.

The New York Times Editorial Board posted a piece worth reading, urging the officials and parties involved in opioid suits to keep at the fore the needs of real people with real injury. Settlements should go with high priority to treating opioid addiction and preventing abuses and overdoses, the newspaper said.

The nonprofit, independent RAND Corporation also has issued the results of its large study about fentanyl, a lab-made opioid that packs a wallop and has become a dangerous and lethal street drug. Fentanyl, the researchers warn, is a menace that constitutes a third phase of the opioid crisis, with prescription meds having been the first wave, opening the gateway to renewed abuse and damage from illicit drugs like heroin, methamphetamine, and cocaine. “Deaths involving synthetic opioids in the United States increased from roughly 3,000 in 2013 to more than 30,000 in 2018,” the researchers reported, adding that policy makers must move with urgency to find ways to get ahead of this next wave of the opioid crisis — or the chaos, death, and disease will only increase and worsen.

If there is a “global” settlement with Big Pharma over the prescription painkiller part of the opioid abuse and overdose crisis how much money also will go to awareness, education, and prevention program, including for threats like fentanyl?

The New York Times harkens to the path-breaking attempts to reach a comprehensive settlement with Big Tobacco over the disease, injury, and other damages associated with cigarette and cigar smoking. That 1998 accord involved 46 states, and, in two decades, payments of $125 billion from Big Tobacco to states. It also was marred by ineffective policies and abuses, the newspaper reported, noting:

“Two decades later, only a fraction of the tobacco proceeds — less than 3% nationally in 2019 — has been spent on public health matters related to tobacco use. In New York, some of the money went to a public golf course. Alabama installed security cameras in its schools. And in North Carolina, a portion of the money was dedicated to subsidies — for tobacco companies. Today, no state finances tobacco control efforts at the level that the Centers for Disease Control and Prevention recommends.”

The newspaper editorial, which says an opioid settlement must be crafted and work better than this, also does not mention that, fundamentally, even a well-intentioned civil justice assault against a damaging product like tobacco may not alter the mendacity of business people who exploit the needs and cravings of their fellow human beings in the most craven ways possible.

Maria Szalavitz, an author who has written on addiction issues, wrote in a New York Times Op-Ed that J&J, doctors, and hospitals have misled too many about the painful picture of those who abuse drugs. Many may be “normal” folks, neighbors who had tooth extractions, got opioids, and got hooked. But may also are desperate souls, drug addicts, in pain, and not pretty:

“Drug companies like Johnson & Johnson twisted the truth about the potential risks of these medications. That caused great harm. Nonetheless, for many — including people with chronic pain or at the end of life — opioids are the only drugs that seem to work. Understanding the facts about these drugs is critical to resolving the crisis and making pharma pay for solutions that work. The reality is this: 80% of those who begin misusing prescription opioids are taking drugs obtained illegally — from theft, dealers, friends, relatives, the internet or other people’s medicine cabinets, not from doctors. And nearly three out of four young people who misuse opioids have previously taken cocaine or crack repeatedly. Indeed, researchers say that prior recreational drug use is a much larger risk factor for opioid addiction than medical exposure. That is not to say that there aren’t some whose addictions begin with a prescription — but this group is a decided minority. This shouldn’t deflect blame from the pharmaceutical industry — as Judge Balkman’s decision suggests, misleading marketing might have helped quadruple medical opioid sales from 1994 to 2006 in Oklahoma. Where those drugs ultimately went and who got harmed, however, is a more complex story than we’ve been led to believe.”

The Los Angeles Times a dozen years ago also warned that Big Pharma, Purdue, in particular, foresaw potential regulatory issues arising in this country, and, so the firms have sought new markets — and people — to exploit elsewhere around the globe. The independent, nonprofit Kaiser Health News service reported that the populous and increasingly wealth nation of India may be a place “ripe for misuse” of opioids. The New York Times reported that the Sacklers may drag their feet over a prospective settlement, partly to protect their options to sell addictive and destructive painkillers in lucrative overseas markets. Is the American opioid crisis something this nation proudly hopes to export to the detriment of the planet?

It’s worth noting that, even as officials grapple with big and complex drug lawsuits and potential settlements, Big Tobacco has morphed, too, in finding new ways to put products before the public that have proven harsh and injurious. In fact, the latest trend for the dark lords of tobacco is vaping and e-cigarettes, a product line so lucrative and alluring that two Big Tobacco giants — Philip Morris and Altria — are in merger talks to create a consumer products behemoth. Curious this, because a key aspect of this deal may rest in Altria’s hope to expand its Juul brand internationally, especially as this vaping market dominating product has run afoul of U.S. health regulators, notably in how vaping may harm kids.

We’ve got a lot of work to do to start to try to keep in check health harming megaliths like Big Pharma and Big Tobacco. It’s a never-ending fight.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Patrick Malone & Associates P.C. | DC Injury Lawyers | Attorney Advertising

Written by:

Patrick Malone & Associates P.C. | DC Injury Lawyers
Contact
more
less

Patrick Malone & Associates P.C. | DC Injury Lawyers on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.